Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

  • STATUS
    Recruiting
  • End date
    Sep 30, 2023
  • participants needed
    43
  • sponsor
    Sun Yat-sen University
Updated on 26 January 2021

Summary

Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy

Description

Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China (Chidamide,a novel histone deacetylase inhibitor). Tirelizumab,has been approved for the failure treatment of platinum-containing chemotherapy with high PD-L1 expression included locally advanced or metastatic Urothelial carcinoma in China(Tirelizumab,BGB-A317 is an investigational humanized IgG4 anti-PD-1 monoclonal antibody ).The aim of this study was to observe the efficacy and safety of Chidamide with Immunotherapy in patients with progression of platinum-based chemotherapy recurrent and metastatic Urothelial carcinoma.

Details
Condition Metastatic Bladder Cancer, Metastatic Bladder Carcinoma, Bladder Cancer Stage IV
Treatment Chidamide with tislelizumab
Clinical Study IdentifierNCT04562311
SponsorSun Yat-sen University
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years, < 75 years
Histopathological diagnosis of transitional cell carcinoma or urothelial carcinoma; It may be associated with other cell types such as small cell carcinoma, neuroendocrine carcinoma or squamous cell carcinoma, but the component should be mainly urothelial carcinoma
Patients with advanced urothelial carcinoma (inoperable or metastatic to lymph nodes or distant metastases) recurred or progressed during adjuvant therapy or advanced first-line platinum-based chemotherapy; Patients receiving secondary chemotherapy may be included, but more than 12 months from the end of the first chemotherapy to the beginning of the second chemotherapy; Subjects who receive neoadjuvant chemotherapy or adjuvant chemotherapy and who develop disease progression within 12 months of the last dose are considered to be receiving systemic chemotherapy in the context of cancer metastasis (disease progression is defined as any progression requiring a change in treatment regimen prior to treatment)
Measurable target lesion (without radiotherapy) : defined as having at least one lesion that can be accurately measured in at least one dimension (the longest diameter recorded), such as 15mm conventional technique or 10mm helical CT scan; Patients with bone metastases may also participate in the study, provided they also have a measurable non-osseous disease
Life expectancy is more than 3 months
ECOG performance status 0~2 (Karnofsky >= 60%)
Bone marrow, liver and renal function adequate: Blood routine examination: neutrophil count 2.0109/L, PLT count 75109/L, WBC count 3.0109/L, hemoglobin concentration 90.0g/dL; Liver function: AST and ALT1.5 times the upper limit of normal value (ULN), alkaline phosphatase 1.5ULN, TBILULN; Cr 1.5 x ULN or less
Left ejection fraction (LVEF) 50%, electrocardiogram (ECG) was generally normal, QTc interphase <0.44 seconds, and there were no signs or symptoms of heart failure
\. Acute toxicity caused by previous treatment is alleviated to level 1 (except hair loss)
The eligibility of patients receiving any drug or substance known or likely to affect cedaramide activity or pharmacokinetics will be determined after review by the principal investigator for a period of more than 6 weeks
Understand and be willing to sign written informed consent documents

Exclusion Criteria

Patients who received chemotherapy (nitrosourea or mitomycin C for 6 weeks) within 4 weeks before the study began, or who did not recover from adverse events due to drug use more than 4 weeks in advance
Patients shall not receive any other anticancer drugs or clinical trial drugs during the clinical trial period (local palliative radiotherapy other than the target lesion may be accepted)
Patients with brain metastases
A history of allergic reactions to compounds that are chemically or biologically similar to cedarbenamine; These compounds include sodium butyrate, Trichostatin A (TSA), Trapoxin (TPX), MS-27-275, and Depsipeptide
Treatment of Urothelial carcinoma with more than two lines or above cytotoxic chemotherapy regiments
Uncontrolled underlying concomitant diseases, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina, arrhythmia, or psychiatric/social conditions, may limit compliance with study requirements
Pregnant women are excluded and should stop breastfeeding if they receive treatment during lactation in the study
Long-term use of immunosuppressive agents after organ transplantation; Patients with autoimmune diseases; Patients who are taking immunosuppressive drugs
HIV positive or have other immunodeficiency diseases
Combined with other active malignancies (i.e., changes in treatment required within the past 24 months). Only patients with skin cancer that has been treated within the past 24 months and has been completely cured are allowed to be enrolled. Localized prostate cancer with Gleason score of 6 (treated or untreated but monitored within the past 24 months); Localized prostate cancer with a Gleason score of 3+4 that was treated more than 12 months prior to full study screening and was completely cured
Live virus vaccine is administered within 30 days of initial administration
Patients should not take valproic acid for at least 2 weeks before entering the study
Due to psychological, social, family, geographical and other reasons can not cooperate with regular follow-up observers
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note